KR20200095452A - 신경퇴행성 질병의 예방 및/또는 치료 - Google Patents

신경퇴행성 질병의 예방 및/또는 치료 Download PDF

Info

Publication number
KR20200095452A
KR20200095452A KR1020207007980A KR20207007980A KR20200095452A KR 20200095452 A KR20200095452 A KR 20200095452A KR 1020207007980 A KR1020207007980 A KR 1020207007980A KR 20207007980 A KR20207007980 A KR 20207007980A KR 20200095452 A KR20200095452 A KR 20200095452A
Authority
KR
South Korea
Prior art keywords
composition
zeaxanthin
omega
lutein
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207007980A
Other languages
English (en)
Korean (ko)
Inventor
앨런 노먼 하워드
존 놀란
리오나 멀카히
Original Assignee
하워드 파운데이션 홀딩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하워드 파운데이션 홀딩스 리미티드 filed Critical 하워드 파운데이션 홀딩스 리미티드
Publication of KR20200095452A publication Critical patent/KR20200095452A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207007980A 2017-12-04 2018-05-10 신경퇴행성 질병의 예방 및/또는 치료 Pending KR20200095452A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
GB1720119.5 2017-12-04
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
KR20200095452A true KR20200095452A (ko) 2020-08-10

Family

ID=60950313

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007980A Pending KR20200095452A (ko) 2017-12-04 2018-05-10 신경퇴행성 질병의 예방 및/또는 치료

Country Status (15)

Country Link
US (1) US10835509B2 (enExample)
EP (2) EP4599891A3 (enExample)
JP (1) JP2021505527A (enExample)
KR (1) KR20200095452A (enExample)
AU (1) AU2018379644B2 (enExample)
BR (1) BR112020005132A2 (enExample)
CA (1) CA3071786C (enExample)
ES (1) ES3047101T3 (enExample)
GB (2) GB201720119D0 (enExample)
IE (1) IE87241B1 (enExample)
MX (1) MX2020002458A (enExample)
RU (1) RU2020111305A (enExample)
SG (1) SG11202000786RA (enExample)
WO (1) WO2019110951A1 (enExample)
ZA (1) ZA202000558B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
TW202313075A (zh) * 2021-05-17 2023-04-01 日商小野藥品工業股份有限公司 用於改善認知功能之組合物
CN120417894A (zh) * 2022-12-26 2025-08-01 三得利控股株式会社 脑神经细胞保护用组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163873A1 (en) 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
EP2219478B1 (en) * 2007-12-17 2017-05-10 Newtricious B.V. Method of producing egg yolk based functional food product and products obtainable thereby
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
ES2675905T3 (es) * 2011-07-07 2018-07-13 Howard Foundation Holdings Limited Método para mejorar la discapacidad por deslumbramiento
DE212013000066U1 (de) * 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
GB201300055D0 (en) * 2013-01-03 2013-02-20 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
HK1211836A1 (en) * 2013-03-28 2016-06-03 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
WO2015005443A1 (ja) * 2013-07-10 2015-01-15 ライオン株式会社 内服組成物
EP3419439B1 (en) * 2016-02-22 2020-04-08 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
IE87241B1 (en) 2021-07-07
CA3071786A1 (en) 2019-06-13
WO2019110951A1 (en) 2019-06-13
US10835509B2 (en) 2020-11-17
AU2018379644A1 (en) 2020-03-19
ES3047101T3 (en) 2025-12-03
EP3644979B1 (en) 2025-08-06
AU2018379644B2 (en) 2024-02-08
GB201720119D0 (en) 2018-01-17
US20190167624A1 (en) 2019-06-06
RU2020111305A (ru) 2022-01-10
GB2568986B (en) 2019-12-18
BR112020005132A2 (pt) 2020-09-15
NZ761512A (en) 2024-01-26
JP2021505527A (ja) 2021-02-18
GB201807590D0 (en) 2018-06-27
ZA202000558B (en) 2021-10-27
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
CA3071786C (en) 2023-11-14
MX2020002458A (es) 2020-07-20
EP4599891A3 (en) 2025-10-22
EP3644979A1 (en) 2020-05-06
SG11202000786RA (en) 2020-06-29
EP4599891A2 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
DK1945045T3 (en) Modermælkserstatninger indeholdende docosahexaensyre og lutein
Konikowska et al. The influence of components of diet on the symptoms of ADHD in children
AU2011260037B2 (en) Dietary formulations
Freeman Omega-3 fatty acids in major depressive disorder.
WO2008082946A1 (en) Method of reducing the risk of retinophathy of prematurity in preterm infants
KR20200095452A (ko) 신경퇴행성 질병의 예방 및/또는 치료
US9040075B2 (en) Method of increasing lean body mass and reducing body fat mass in infants
WO2016013617A1 (ja) 脳機能改善剤、及び認知機能障害の予防または治療剤
CA2599112A1 (en) Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
JP6669761B2 (ja) 不安神経症を治療するための中鎖脂肪酸及びそれらのトリグリセリド
US20200197349A1 (en) Cognitive function
Partinen et al. Nutrition, sleep and sleep disorders–relations of some food constituents and sleep
US9107891B2 (en) Method for alleviating fear memory
US20190307715A1 (en) Prevention and/or treatment of neurodegenerative disease
Horowitz Omega-3 fatty acids for disease prevention and treatment
JP2008044894A (ja) メタボリックシンドローム改善剤
Page Macular pigment optical density during pregnancy and its relationship to the diet
IES85984Y1 (en) Dietary formulations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)